Embecta Corp., (EMBC) News
Filter EMBC News Items
EMBC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EMBC News Highlights
- For EMBC, its 30 day story count is now at 3.
- Over the past 7 days, the trend for EMBC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about EMBC are DEC.
Latest EMBC News From Around the Web
Below are the latest news stories about EMBECTA CORP that investors may wish to consider to help them evaluate EMBC as an investment opportunity.
Zacks Investment Ideas feature highlights: Beacon Roofing Supply, Embecta and Western Midstream PartnersBeacon Roofing Supply, Embecta and Western Midstream Partners have been highlighted in this Investment Ideas article. |
Time to Buy These Intriguing Additions to Zacks Rank #1 (Strong Buy) ListSeveral intriguing stocks were recently added to the Zacks Rank #1 (Strong Buy) list this week and shouldn't be overlooked as we round out what has been an exciting year for the stock market. |
embecta to Participate at the 42nd Annual J.P. Morgan Healthcare ConferencePARSIPPANY, N.J., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 2:15 p.m. PT / 5:15 p.m. ET. Audio webcasts of the presentations will be accessible under the “News & Events” section of the Company's investor relations website at investors.embecta.com. About embecta embecta is a global diabetes care company that is leveraging its nearl |
No embecta-made syringes impacted by FDA safety communicationPARSIPPANY, N.J., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, today issued the following statement regarding the U.S. Food and Drug Administration (FDA) Safety Communication on evaluation of certain plastic syringes: “embecta, the world’s largest manufacturer of plastic insulin syringes, manufactures all of our syringes distributed worldwide at our facility in Holdrege, Nebraska,” said Shaun Curtis, SVP, Global Manufacturing & Suppl |
Embecta Corp's Dividend AnalysisEmbecta Corp(NASDAQ:EMBC) recently announced a dividend of $0.15 per share, payable on 2023-12-15, with the ex-dividend date set for 2023-12-01. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Embecta Corps dividend performance and assess its sustainability. |
embecta to Participate in Investor ConferencesPARSIPPANY, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, today announced that management will participate in the following investor events: 2023 Mizuho Medical Device and Healthcare Services Summit Management will host one-on-one investor meetings on Wednesday, December 6, 2023, at Sofitel Hotel, New York. 2023 MedTech Madness Annual West Coast Bus Tour Management will host a fireside session on Monday, December 11, 2023, at 9: |
Should Income Investors Look At Embecta Corp. (NASDAQ:EMBC) Before Its Ex-Dividend?Embecta Corp. ( NASDAQ:EMBC ) is about to trade ex-dividend in the next 4 days. The ex-dividend date is one business... |
Embecta Corp. (NASDAQ:EMBC) Q4 2023 Earnings Call TranscriptEmbecta Corp. (NASDAQ:EMBC) Q4 2023 Earnings Call Transcript November 21, 2023 Embecta Corp. beats earnings expectations. Reported EPS is $0.59, expectations were $0.42. Operator: Welcome, ladies and gentlemen, to the Fiscal Fourth Quarter and Full Year 2023 embecta Earnings Conference Call. at this time, all participants have been placed in a listen-only mode. Please note […] |
Embecta CEO Dev Kurdikar talks about growth expectations, GLP-1sThe CEO said the company’s growth expectations have not changed in the near term, even with the rise of weight loss drugs. |
Embecta Corp. (EMBC) Beats Q4 Earnings and Revenue EstimatesEmbecta Corp. (EMBC) delivered earnings and revenue surprises of 40.48% and 1.75%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |